Single-Arm Phase 2 Study of Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Eligible for Intensive Induction Chemotherapy
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Olutasidenib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms OLUVENAZA
- 23 Jan 2025 New trial record